Primary biliary cholangitis
|
|
- Doreen Peters
- 5 years ago
- Views:
Transcription
1 A guide to Primary biliary cholangitis Miss Jennifer Hayden, Autoimmune Liver Disease Clinical Nurse Specialist Professor Gideon M Hirschfield, Professor and Consultant Transplant Hepatologist Centre for Liver Research, NIHR Biomedical Research Centre, University of Birmingham, and Centre for Rare Diseases, Institute of Translational Medicine, Birmingham Health Partners, University Hospitals Birmingham, Birmingham B15 2TT Correspondence to: Professor GM Hirschfield (g.hirschfield@bham.ac.uk) This booklet was sponsored by Intercept Pharma UK & Ireland Ltd. The sponsoring company has had no editorial control over the content, except to review the document for factual accuracy. Job Code: UK-NP-PB-0222 Date of Preparation: December 2017
2 Introduction The autoimmune biliary disease primary biliary cholangitis (formerly known as primary biliary cirrhosis) is a chronic inflammatory liver disease that is characterised by persistent immunedriven biliary injury (Table 1). This results in cholestasis, progressive liver fibrosis, and for some patients end-stage liver disease. Disease is usually identified in a patient with a cholestatic pattern of serum liver tests elevated levels of alkaline phosphatase and/or gamma-glutamyltransferase and the presence of circulating anti-mitochondrial antibodies (Hirschfield and Gershwin, 2013). In contrast to other liver diseases, most patients living with primary biliary cholangitis are women and the average age at presentation is between 50 and 60 years. The estimates for prevalence in the UK suggest that at least 1 in 1000 women over the age of 40 years live with primary biliary cholangitis (Hirschfield et al, 2017). The incidence of new diagnoses of primary biliary cholangitis is around 2 3 per per year (Hirschfield et al, 2017). Paradoxically for what is considered an archetypal autoimmune disease, children do not develop primary biliary cholangitis. Men with primary biliary cholangitis have the same diagnostic characteristics but their disease course tends to be more serious, either because they present at diagnosis with more advanced disease, or because their response to first-line therapy with ursodeoxycholic acid appears reduced (Trivedi et al, 2016). At the time of diagnosis, most patients with primary biliary cholangitis report few if any symptoms. However, many patients develop symptoms that can be burdensome, and these may be specific or non-specific. Within the symptom complex associated with primary biliary cholangitis are pruritus, sicca complex, abdominal discomfort, fatigue, bone pain and restless legs. It is notable that symptom burden need not directly correlate with disease severity, albeit that patients presenting at a young age with more aggressive disease may be particularly troubled with pruritus, and patients with late stage disease are inevitably frequently more symptomatic. Pathogenesis The aetiology of primary biliary cholangitis is believed to result from a combination of genetic and Table 1. Primary biliary cholangitis: an overview Age Sex Female > male (9:1) Serology Immunoglobulin Imaging Liver histology Symptoms Licenced treatment options Follow up Usually >45 years; diagnosis <45 years associated with higher risk of progression Anti-mitochondrial antibody in ~95%, disease-specific anti-nuclear antibody in ~30 50%, antismooth muscle antibody may be present IgM typically elevated (sensitive but not specific for primary biliary cholangitis) Normal bile ducts Rarely indicated; lymphocytic infiltrate, inflammatory duct lesion, granuloma possible Pruritus, bone pain, fatigue, sicca, restless legs Ursodexycholic acid (13 15 mg/kg/day); obeticholic acid (5 10 mg/day, dose adjust for patients with Child Pugh score B/C) Ambulatory care, 6 12 months; variable burden
3 environmental triggers, although precise causation continues to be evasive, and as such there are no treatments that cure patients (Hirschfield and Gershwin, 2013; Webb and Hirschfield, 2017). Studies have shown many genetic variations which predispose an individual to developing primary biliary cholangitis, and the genes highlighted appear relevant to immune regulation; an exemplar of this is the interleukin-12 signalling pathway. Geo-epidemiological studies in patients with primary biliary cholangitis repeatedly support the likely involvement of environmental triggers, with immunological studies demonstrating potential pathogenic mechanisms through xenobiotics and molecular mimicry that relate environmental triggers to loss of immune tolerance to the key auto-antigen, pyruvate dehydrogenase. Other insights into disease have also arisen from population studies which demonstrate how patients with primary biliary cholangitis are more likely to have smoked cigarettes than those without disease, and to have a higher rate of recurrent urinary tract infections. The striking gender imbalance and late onset of disease for the majority of cases support added epigenetic mechanisms relevant to disease expression. Diagnosis Of the three autoimmune liver diseases, primary biliary cholangitis is the most straightforward to diagnose, and for the majority of patients a confident diagnosis can be made in the correct clinical context, based on a combination of cholestatic liver biochemistry and the presence of anti-mitochondrial antibodies. Liver biopsy is therefore an infrequent investigation in the diagnostic pathway, although a role persists in the absence of characteristic serological reactivity, where features of autoimmune hepatitis are also present, or in cases where it is unclear if there could be an added liver injury such as nonalcoholic fatty liver disease. The predominant pattern recognised by serum liver tests in patients with primary biliary cholangitis is a rise in alkaline phosphatase levels. A concomitant rise in gamma-glutamyltransferase levels is consistent with a biliary origin for the increased alkaline phosphatase levels. There may also be elevations in aminotransferase levels, but these are usually not as marked; values above five times the upper limit of normal are uncommon in classically presenting primary biliary cholangitis (Hirschfield et al, 2017). The purpose of arranging a baseline ultrasound is not to visualise primary biliary cholangitis (it being a small bile duct disease) but to exclude biliary obstruction as an aetiology for cholestatic liver tests, as well as to look for features of cirrhosis and portal hypertension. No additional imaging is normally needed. With disease progression, particularly in those with baseline risk factors for high-risk disease, or those who fail to respond adequately to therapy, patients may show features of advanced liver disease such as jaundice, hepatomegaly and splenomegaly. Immuno-serology, which critically must always be interpreted in the context of a patient s overall clinical presentation, is key to diagnosing autoimmune liver disease, and in particular primary biliary cholangitis. Over 90% of patients will be anti-mitochondrial antibody-positive. This is often accompanied by a non-specific rise in IgM concentrations. A small percentage of patients with primary biliary cholangitis are negative for anti-mitochondrial antibodies. In this setting immunofluorescence patterns of anti-nuclear antibodies may help, notably multi-nuclear dot and peri-nuclear rim reactivity, as well as centromere reactivity. Specific immunoassays related to anti-nuclear reactivities may reveal anti-gp210 or antisp100 reactivity which are both very specific for primary biliary cholangitis.
4 Clinical consequence of disease With current treatment, and in contrast to previous eras, the overwhelming majority of patients are diagnosed early in their disease course and treated proactively; all should be offered ursodeoxycholic acid first line. A licenced secondline therapy in the form of obeticholic acid became available in the UK in Transplant rates for primary biliary cholangitis have subsequently fallen over time (Webb et al, 2017). Nevertheless morbidity and mortality remains real and survival in primary biliary cholangitis is associated with baseline and on-treatment risk factors. Those patients who are male, are diagnosed at a younger age (<45 years) and/or present with advanced disease have greater risk of disease progression. Furthermore, patients with biochemical disease activity (i.e. elevations in alkaline phosphatase and/or serum aminotransferase activity values) despite therapy with ursodeoxycholic acid have greater likelihood of progressive disease (Lammers et al, 2014; Trivedi et al, 2016). The development of progressive biliary disease is associated with portal hypertension, liver failure and hepatocellular carcinoma risk. Stratification of risk The goal of treatment is to ensure each individual is managed in a way that reflects the disease course of primary biliary cholangitis for that person, including symptoms. Therefore therapeutic strategies for primary biliary cholangitis should evaluate a patient s risk of disease progression, together with an assessment of the present disease stage and the patient s symptom burden. To stage liver disease in primary biliary cholangitis, attention is given to markers of disease severity bilirubin values and platelet count in particular as well as imaging findings, encompassing evidence of cirrhotic liver morphology and/or presence of splenomegaly on ultrasound, as well as interpretation of serial transient elastography. Staging is important as those with advanced liver disease have a higher risk of future disease progression. With effective interventions predicted to be most beneficial if offered before late stage disease, patients are evaluated for risk of progressive liver disease from the point of diagnosis and treatment (Trivedi et al, 2016). This process needs to account for both baseline risk factors (e.g. young age at diagnosis (<45 years) and advanced stage at presentation, particularly cirrhosis and elevated bilirubin levels), as well as on-treatment (biochemical response) predictors of future risk. Multiple studies (Lammers et al, 2014; Trivedi et al, 2016) demonstrate a high risk of adverse events for patients with inadequate response to ursodeoxycholic acid treatment usually judged 1 year after initiation. The definitions of inadequate biochemical response to ursodeoxycholic acid vary, but all encompass an evaluation of serum liver tests, in particular bilirubin and alkaline phosphatase levels. Interface hepatitis is a histological marker of poor prognosis and persistent serum aminotransferase elevations are also identifiable as risk markers. There are a variety of reported tools (Trivedi et al, 2016), some dichotomous, others continuous, such as the GLOBE score and UK-PBC score. Of these, one simple, widely applied criterion used in clinical trials of new therapies is to define high-risk disease as those patients having elevated bilirubin levels and/or an alkaline phosphatase level greater than 1.67 times the upper limit of normal (Nevens et al, 2016). Treatment Management of primary biliary cholangitis focuses on: 1. Confirming the diagnosis clearly to the patient 2. Recognising the severity of liver disease at presentation and during follow up 3. Identifying the patients at greatest risk of disease progression based on baseline presenting
5 features and importantly ongoing response to treatment 4. Ensuring that, beyond effective disease-specific therapy, attention is focused on managing the complications of chronic cholestatic liver disease and understanding and intervening as able with the varied symptom complex of patients. Patient management usually spans primary and secondary care settings, with tertiary programmes focusing on those at greatest risk or with greatest symptom burden. Furthermore nurse specialist care is valuable, and a means to both attending to the need for patient education, but also timely input and guidance for symptom control, as well as safe monitoring of therapies such as obeticholic acid and rifampicin. The important pathophysiological processes underlying primary biliary cholangitis are inflammation, cholestasis and fibrosis. No therapy to date has been able to cure disease; rather they modify these underlying consequences of persistent immune-mediated biliary-driven injury. Across this spectrum of targets biologic-based therapies have been disappointing and therapy to date has focused on bile acid-based drugs, which modify cholestasis and associated inflammation, and subsequent fibrogenesis. Ursodeoxycholic acid is a naturally occurring secondary bile acid (an epimer of chenodeoxycholic acid) that, in gram quantities, is choleretic and anti-inflammatory. Obeticholic acid is a semi-synthetic bile acid (6α-ethyl-chenodeoxycholic acid) that, in miligram quantities, is a selective farnesoid X receptor agonist, with anti-inflammatory, antifibrotic and choleretic properties (Beuers et al, 2015). Once a patient has been diagnosed with primary biliary cholangitis, guidelines from Europe (Hirschfield et al, 2017) and the USA (Lindor et al, 2009) both suggest that all patients should be offered treatment with weight-based ursodeoxycholic acid (13 15 mg/kg/day) with the intention that treatment will be for life. For a majority of patients, ursodeoxycholic acid (safely taken once, twice or three times/day as per patient choice) is well tolerated, side effects being limited to bloating, weight gain and thinning of hair. Biochemical response to treatment with ursodeoxycholic acid is an important marker of treatment success, and it is associated with prolonged survival. For those patients with noncirrhotic liver disease who achieve a complete response to therapy biochemically, survival is excellent, and in some series, no different to an age-matched healthy control population. If patients are either intolerant of ursodeoxycholic acid therapy, or biochemically do not achieve a sufficient response, accounting for their baseline risk, then second-line licenced therapy in the form of added obeticholic acid should be considered (Hirschfield et al, 2017). In the UK, obeticholic acid is started at 5 mg daily, and titrated if tolerated at 6 months to 10 mg daily. In a phase 3 clinical trial of obeticholic acid, nearly half of high-risk patients were deemed biochemical responders to therapy (Nevens et al, 2016). In using obeticholic acid it is important to assess the likelihood of benefit. In those patients with advanced disease dose adjustment is important. As per the drug label, obeticholic acid is dose adjusted to 5 mg weekly initially (with a maximum dose of 10 mg twice weekly) in those with liver disease with a Child Pugh B or C score. The authors practice when initiating therapy in a patient with a Child Pugh A score is to also dose adjust in the presence of portal hypertension. Cirrhotic patients should have intensified early safety evaluation in particular, and in the context of development of decompensation for a patient on obeticholic acid, dose adjustment or treatment cessation may be indicated. Pruritus is a side effect of obeticholic acid, but in clinical trial settings, treatment discontinuation
6 overall is less than 10% at labelled doses of obeticholic acid; dose titration is important in this respect. The pruritus associated with obeticholic acid should be treated by either cholestyramine or rifampicin or by adjusting the dose of obeticholic acid. Treatment efficacy is evaluated by followup serum liver tests, with the therapeutic goal of improving markers of liver injury namely a fall in alkaline phosphatase level and stabilisation of bilirubin level. Other agents used globally for primary biliary cholangitis include fibrates (a non-labelled indication) and there remain many clinical trial agents in development (Beuers et al, 2015). Symptoms should also be sought and actively managed. Medical treatments for itch can be very successful, and patients are usually started on the bile acid resin cholestyramine first. Rifampicin is used second line, but its use does require blood test monitoring, as there is a small risk of hepatotoxicity in particular. Other agents for itch include sertraline and naltrexone. Fatigue does not have a specific medical treatment, but exercise is frequently anecdotally reported as helpful. Managing complications The management of cirrhosis in the context of primary biliary cholangitis is akin to that of any patient with chronic liver disease, with priority given to diagnosing hepatocellular carcinoma early, preventing variceal haemorrhage and reducing the risk of osteoporotic fracture. Nuances include a potential for non-cirrhotic portal hypertension rarely in patients with primary biliary cholangitis, and a recognition that hepatocellular carcinoma risk is skewed in patients with primary biliary cholangitis to those with advanced liver disease, treatment non-responders and male patients. As liver disease progresses patients are followed by repeated serum liver tests, imaging and elastography, all of which help define the pattern of disease progression, as well as identifying surveillance needs, including timing of endoscopy for varices. In patients who develop persistent jaundice (>50 mmol/litre), decompensated liver disease or intractable pruritus, liver transplantation should be considered, as it is a highly effective intervention. Listing for transplantation usually requires a disease severity score consistent with accepting the risk of surgery alongside an overt indication (Hirschfield et al, 2017). Other features associated with primary biliary cholangitis are low bone-mass from osteoporosis and hyperlipidaemia associated with cholestasis. Patients are usually recommended to take calcium and vitamin D supplements and to have a bone-density evaluation, as well as a general bone-fracture risk evaluation. The cholestasis of primary biliary cholangitis is also associated with a lipogenic, non-atherogenic profile characterised by high levels of cholesterol and high-density lipoproteins and tissue deposits of lipids (referred to as xanthelasma) (Hirschfield et al, 2017). The hyperlipidaemia of primary biliary cholangitis is usually not a concern, only requiring intervention if there are added metabolic or cardiac risks. Standard pharmacological approaches to managing the hyperlipidaemia can be offered, if indicated. Routine screening for associated autoimmune diseases in patients with primary biliary cholangitis is not evidence based, but consideration should be given to the higher rate of thyroid disease and coeliac disease in this cohort of patients in particular. Conclusions Patients with primary biliary cholangitis live with the consequences of a chronic persistent biliary injury that, if untreated, progresses to end-stage liver disease. Therapies are increasingly effective, and licenced options for care now include, beyond ursodexoycholic acid, therapy with a selective bile acid-based farnesoid X receptor agonist, obeticholic acid. Overall care is thus more sophisticated
7 and attention to appropriate risk stratification and early access to additional disease-modifying therapy is important. This rests alongside the need to tackle the associated symptom burden that patients with primary biliary cholangitis have, in a way that is proactive and directed. Conflict of interest: Miss J Hayden and Professor GM Hirschfield have received speaker fees from Falk Pharma and Intercept Pharmaceuticals. This guide presents independent research supported by the NIHR Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Cover image from Adobe Stock/PIC4U Beuers U, Trauner M, Jansen P, Poupon R (2015) New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol 62(1): S25 S37. Hirschfield GM, Gershwin ME (2013) The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol 8: Hirschfield GM, Beuers U, Corpechot C et al (2017) EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol 67(1): jhep Lammers WJ, van Buuren HR, Hirschfield GM et al (2014) Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 147(6): e5. gastro Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases (2009) Primary biliary cirrhosis. Hepatology 50(1): Nevens F, Andreone P, Mazzella G et al (2016) A placebocontrolled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 375(7): org/ /nejmoa Trivedi PJ, Corpechot C, Pares A, Hirschfield GM (2016) Risk stratification in autoimmune cholestatic liver diseases: opportunities for clinicians and trialists. Hepatology 63(2): Webb GJ, Hirschfield GM (2017) Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances. Nat Rev Gastroenterol Hepatol 14(2): Webb GJ, Rana A, Hodson J et al (2017) Twenty-year comparative analysis of patients with autoimmune liver diseases on transplant waitlists. Clin Gastroenterol Hepatol
8 Abbreviated Prescribing Information OCALIVA (obeticholic acid) (Please refer to the Full Summary of Product Characteristics (SmPC) before prescribing) Presentation: OCALIVA supplied as film-coated tablets containing 5 mg and 10 mg obeticholic acid. Indication: For the treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. Dosage and administration: Oral administration. The starting dose is 5 mg once daily. Based on an assessment of tolerability after 6 months, the dose should be increased to 10 mg once daily to achieve optimal response. No dose adjustment of concomitant UDCA is required in patients receiving obeticholic acid. For cases of severe pruritus, dose management includes dose adjustment such as reduced dosage, temporal interruption or discontinuation for persistent intolerable pruritus; use of bile acid binding agents or antihistamines (see SmPC). No dosage adjustment for elderly. Renal impairment: No dose adjustments are required. Hepatic impairment: No dose adjustment for mild hepatic impairment (Child-Pugh Class A). The recommended starting dosage for moderate/ and severe (Child-Pugh Class B/C) hepatic impairment is 5 mg once weekly. Titrate to 5 mg and subsequently to 10 mg twice weekly (at least 3 days between doses) if patient does not achieve adequate reductions in alkaline phosphatase and/or total bilirubin after 3 months, depending on response and tolerability. Paediatric population: No data. Contraindications: Hypersensitivity to the active substance or any excipients. Complete biliary obstruction. Special warnings and precautions for use: Liver-related adverse events occurring as early as within the first month of treatment; elevations in alanine amino transferase (ALT), aspartate aminotransferase (AST) and hepatic decompensation have been observed and patients should be monitored during treatment with OCALIVA. Severe pruritus; see recommendations for dosage reduction and use of bile acid binding resins or antihistamines. Interactions: Following co-administration of warfarin and obeticholic acid. International normalised ratio (INR) should be monitored and the dose of warfarin adjusted, if needed, to maintain the target INR range. Therapeutic monitoring of CYP1A2 substrates with narrow therapeutic index (e.g. theophylline and tizanidine) is recommended. Obeticholic acid should be taken at least 4-6 hours before or after taking a bile acid binding resin, or at as great an interval as possible. Fertility, pregnancy and lactation: Avoid use in pregnancy. Either discontinue breast-feeding or discontinue/abstain from obeticholic acid therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman. No clinical data on fertility effects. Undesirable effects: Very common ( 1/10) adverse reactions were pruritus, fatigue, and abdominal pain and discomfort. The most common adverse reaction leading to discontinuation was pruritus. The majority of pruritus occurred within the first month of treatment and tended to resolve over time with continued dosing. Other commonly ( 1/100 to < 1/10) reported adverse reactions are, thyroid function abnormality, dizziness, palpitations, oropharyngeal pain, constipation, eczema, rash, arthralgia, peripheral oedema, and pyrexia. Please refer to the SmPC for a full list of undesirable effects. Overdose: Liver-related adverse reactions were reported with higher than recommended doses of obeticholic acid. Patients should be carefully observed and supportive care administered, as appropriate. Legal category: POM Marketing authorisation numbers: EU/1/16/1139/001 & 002 Marketing authorisation holder: Intercept Pharma Ltd, 2 Pancras Square, London, N1C 4AG, United Kingdom Package Quantities and Basic NHS cost: OCALIVA 5 mg and 10 mg 2, per bottle of 30 tablets. Date of revision: 20/DEC/2016 Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Intercept Pharma Ltd on +44 (0) or drugsafety@interceptpharma.com
Diagnosis and Management of PBC
Diagnosis and Management of PBC Cynthia Levy, MD, FAASLD University of Miami Miller School of Medicine Miami, Florida 1 Primary Biliary Cholangitis (PBC) Chronic cholestatic liver disease Autoimmune in
More informationMY DISCUSSION GUIDE. Personalize your treatment plan for primary biliary cholangitis (PBC).
I am not on OCALIVA (obeticholic acid) MY DISCUSSION GUIDE Personalize your treatment plan for primary biliary cholangitis (PBC). This guide is not intended to replace the advice of your healthcare team.
More informationOcaliva (obeticholic acid tablets)
Ocaliva (obeticholic acid tablets) Policy Number: 5.01.619 Last Review: 11/2018 Origination: 11/2016 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationMY DISCUSSION GUIDE. Get the most out of your OCALIVA treatment.
PBC I am currently taking OCALIVA (obeticholic acid) MY DISCUSSION GUIDE Get the most out of your OCALIVA treatment. This guide is not intended to replace the advice of your healthcare team. All decisions
More informationSubject: Obeticholic Acid (Ocaliva ) Tablet
09-J2000-65 Original Effective Date: 09/15/16 Reviewed: 07/11/18 Revised: 08/15/18 Subject: Obeticholic Acid (Ocaliva ) Tablet THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis PBC Foundation (UK) Ltd 6 Hill Street Edinburgh EH2 3JZ Tel: +44 (0) 131 556 6811 info@pbcfoundation.org.uk www.pbcfoundation.org.uk PBC for Healthcare Practitioners Introduction
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Ocaliva (obeticholic acid) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ocaliva (obeticholic acid) Prime Therapeutics will review Prior Authorization
More informationNew insights in pathogenesis and therapy of primary biliary cholangitis. Keith D. Lindor Dean Professor of Medicine
New insights in pathogenesis and therapy of primary biliary cholangitis Keith D. Lindor Dean Professor of Medicine OUTLINE PBC Epidemiology Diagnosis Treatment Incidence of PBC and PSC Trends Boonstra
More informationWELCOME TO YOUR WORLD OF PBC TREATMENT Adding OCALIVA (obeticholic acid) to your treatment plan starts here.
WELCOME TO YOUR WORLD OF PBC TREATMENT Adding OCALIVA (obeticholic acid) to your treatment plan starts here. Photograph of an actual patient What is OCALIVA? OCALIVA is a prescription medicine used to
More informationSingle Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785
Single Technology Appraisal (STA) Obeticholic acid for treating primary biliary cirrhosis ID785 Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Comment
More informationPBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?
22 November 2018 BD-IAP UK-LPG Liver Update PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? in a UDCA non-responder Dina G. Tiniakos Institute of Cellular Medicine, Faculty of Medical
More informationPBC treatment: the present and future. Maggie Bassendine Professor of Hepatology
PBC treatment: the present and future Maggie Bassendine Professor of Hepatology Primary biliary cirrhosis 20-25yrs OLT/ Death Symptoms: Fatigue, itching, jaundice Autoimmune disease: Focal small bile duct
More informationWELCOME TO YOUR WORLD OF PBC TREATMENT Adding OCALIVA (obeticholic acid) to your treatment plan starts here.
WELCOME TO YOUR WORLD OF PBC TREATMENT Adding OCALIVA (obeticholic acid) to your treatment plan starts here. Photograph of an actual patient. What is OCALIVA? OCALIVA (obeticholic acid) is a prescription
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis What is primary biliary cholangitis? Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic liver disease. When a person has PBC, the immune
More informationSOMEONE YOU CARE ABOUT HAS PBC Learn about primary biliary cholangitis (PBC), the treatment, and ways you can help
SOMEONE YOU CARE ABOUT HAS PBC Learn about primary biliary cholangitis (PBC), the treatment, and ways you can help Photograph of an actual patient and family member. What is OCALIVA (obeticholic acid)?
More informationOverview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN
Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN 2012 Annual Conference PSC Partners Seeking a Cure May 5, 2012 Primary Sclerosing Cholangitis Multifocal
More informationChild-Pugh Class B or C or Patients with a Prior Decompensation Event a 5 mg once daily 5 mg once weekly. Compensated Child- Pugh Class A
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OCALIVA safely and effectively. See full prescribing information for OCALIVA. OCALIVA (obeticholic
More informationHangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam
Clinical Aspects of Primary Biliary Cirrhosis Hangzhou, 15 March 2008 Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam Epidemiology of Primary
More informationObeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks
Obeticholic Acid for the treatment of Primary Biliary Cholangitis: Effectiveness, Value, and Value-Based Price Benchmarks Draft Background and Scope Background: April 21, 2016 Primary biliary cholangitis
More informationPediatric PSC A children s tale
Pediatric PSC A children s tale September 8 th PSC Partners seeking a cure Tamir Miloh Assistant Professor Pediatric Hepatology Mount Sinai Hospital, NY Incidence Primary Sclerosing Cholangitis (PSC) ;
More informationCurrent Concepts in the Management and Treatment of PBC & PSC
Current Concepts in the Management and Treatment of PBC & PSC Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London A family affair? Central vein Hepatocytes
More informationTREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC)
TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC) URSO not indicated Therapy for PBC Difficulties Etiology is uncertain Therapies are based on ideas regarding pathogenesis Present medical therapies have a limited
More informationYou and OCALIVA (obeticholic acid) The importance of staying on treatment
You and OCALIVA (obeticholic acid) The importance of staying on treatment What is OCALIVA? OCALIVA is a prescription medicine used to treat primary biliary cholangitis (PBC) in combination with ursodeoxycholic
More informationValdoxan (agomelatine) in the treatment of Major Depressive Episodes in Adults. Prescriber Guide Information for Healthcare Professionals
Important information Do not discard! Valdoxan (agomelatine) in the treatment of Major Depressive Episodes in Adults Prescriber Guide Information for Healthcare Professionals Recommendations regarding:
More informationRisk stratification in PBC
Risk stratification in PBC Christophe Corpechot Reference Center for Inflammatory Biliary Diseases Saint-Antoine hospital, Paris, France What is currently known (background) PBC : chronic, progressive
More informationMorning Report Presentation. Sarah Hughes, MD January 11, 2005
Morning Report Presentation Sarah Hughes, MD January 11, 2005 Primary Biliary Cirrhosis! PBC is a chronic, progressive, cholestatic liver disease of unknown cause that usually affects middle-aged women
More informationONE REGIMEN, ALL GENOTYPES, 8 WEEKS
For UK healthcare professionals only INTRODUCING MAVIRET ONE REGIMEN, ALL GENOTYPES, 8 WEEKS FOR TREATMENT-NAÏVE, NON-CIRRHOTIC PATIENTS 1 Maviret is indicated for the treatment of chronic hepatitis C
More informationPrimary Biliary Cirrhosis
Primary Biliary Cirrhosis What is Primary Biliary Cirrhosis? Primary biliary cirrhosis (PBC) is a chronic liver disease resulting from progressive destruction of the bile ducts in the liver called the
More informationProgram Disclosure. This activity is supported by an educational grant from Intercept Pharmaceuticals.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership
More informationKa-Shing Cheung, MBBS, MPH 1, Wai-Kay Seto, MD 1,2, James Fung, MD 1,2, Ching-Lung Lai, MD 1,2 and Man-Fung Yuen, MD, PhD 1,2
Citation: (2017) 8, e100; doi:10.1038/ctg.2017.23 Official journal of the American College of Gastroenterology www.nature.com/ctg Prognostic Factors for Transplant-Free Survival and Validation of Prognostic
More informationAutoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP
Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:
More informationKey Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto
Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective Jenny Heathcote, MD University of Toronto Key Points: AILD comprise autoimmune hepatitis, primary biliary cirrhosis
More informationChronic Cholestatic Liver Diseases
Chronic Cholestatic Liver Diseases - EASL Clinical Practice Guidelines - Rome, 8 October 2010 Ulrich Beuers Department of Gastroenterology and Hepatology Tytgat Institute of Liver and Intestinal Research
More informationHépatopathies auto-immunes
16 ème Journée d'automne Lausanne, le 19 octobre 2017 Hépatopathies auto-immunes Nurullah Aslan et Darius Moradpour Service de Gastroentérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationHepatocytes produce. Proteins Clotting factors Hormones. Bile Flow
R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon
More informationImproving the Lives of Patients with Liver Diseases
Improving the Lives of Patients with Liver Diseases Corporate Presentation March 2019 Safe Harbor Statement This presentation contains "forward-looking" statements that involve risks, uncertainties and
More informationA Review of Liver Function Tests. James Gray Gastroenterology Vancouver
A Review of Liver Function Tests James Gray Gastroenterology Vancouver Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationTHE BRITISH SOCIETY OF GASTROENTEROLOGY/UK-PBC PRIMARY BILIARY CHOLANGITIS TREATMENT AND MANAGEMENT GUIDELINES
THE BRITISH SOCIETY OF GASTROENTEROLOGY/UK-PBC PRIMARY BILIARY CHOLANGITIS TREATMENT AND MANAGEMENT GUIDELINES AUTHORS: HIRSCHFIELD GM, DYSON JK, ALEXANDER GJ, CHAPMAN M, COLLIER J, HUBSCHER S, PATANWALA
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION OCALIVA. Obeticholic acid. 5 mg and 10 mg Tablets. Farnesoid X Receptor (FXR) Agonist
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr OCALIVA Obeticholic acid 5 mg and 10 mg Tablets Farnesoid X Receptor (FXR) Agonist OCALIVA, indicated for the treatment of primary biliary
More informationOCALIVA (obeticholic acid) oral tablet
OCALIVA (obeticholic acid) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationEnroll in Interconnect
Enroll in Interconnect Enrollment Form Checklist In this packet, you will find all of the necessary forms to enroll your patients in Interconnect and give them access to a full suite of support services
More informationPrognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark
Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark Study of Prognosis of PSC Difficulties: Disease is rare The duration of the course of disease may be very
More informationI have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES
LIVER TESTS: HOW TO UTILIZE THEM I have no disclosures relevant to this presentation José Franco, MD Professor of Medicine, Surgery and Pediatrics Medical College of Wisconsin OBJECTIVES Differentiate
More informationDOSING AND ADMINISTRATION GUIDE
DOSING AND ADMINISTRATION GUIDE Indication TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient
More informationPrimary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants
Primary Sclerosing Cholangitis and Cholestatic liver diseases Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants I have nothing to disclose Educational Objectives What is PSC? Understand the cholestatic
More informationCONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients
Galvus PRESENTATION: Each tablet contains 50 mg of Vildagliptin INDICATIONS: For the treatment of type 2 diabetes mellitus in adults: i) As monotherapy in patients inadequately controlled by diet and exercise
More informationPRIMARY BILIARY CHOLANGITIS: DIAGNOSIS AND MANAGEMENT Project ID:
ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint
More informationShifting Paradigms in Primary Biliary Cholangitis A CE/CME Activity
Overview Shifting Paradigms in Primary Biliary Cholangitis A CE/CME Activity In this video series, Kris Kowdley, MD, and Seth Sclair, MD, share insight into changes in the management of patients with primary
More informationNoncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis
Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids Cholestasis Biochemical hallmark Impaired bile flow from liver to small intestine Alkaline phosphatase is primary
More informationPRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION OCALIVA. Obeticholic acid. 5 mg and 10 mg Tablets. Farnesoid X Receptor (FXR) Agonist
PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr OCALIVA Obeticholic acid 5 mg and 10 mg Tablets Farnesoid X Receptor (FXR) Agonist OCALIVA, indicated for the treatment of primary biliary
More informationIntercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
July 31, 2017 Intercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update Worldwide net Ocaliva (obeticholic acid or OCA) 2Q 2017 sales of $30.4 million AESOP Phase
More informationPutting NICE guidance into practice. Resource impact report: Obeticholic acid for treating primary biliary cholangitis (TA443)
Putting NICE guidance into practice Resource impact report: Obeticholic acid for treating primary biliary cholangitis (TA443) Published: April 2017 Summary Obeticholic acid is recommended as an option
More informationACG Clinical Guideline: Primary Sclerosing Cholangitis
ACG Clinical Guideline: Primary Sclerosing Cholangitis Keith D. Lindor, MD, FACG 1, Kris V. Kowdley, MD, FACG 2, and M. Edwyn Harrison, MD 3 1 College of Health Solutions, Arizona State University, Phoenix,
More informationPRESCRIBING INFORMATION (PI)
PRESCRIBING INFORMATION (PI) BYDUREON (exenatide) 2MG POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION BYETTA (exenatide) 5 MICROGRAMS AND 10 MICROGRAMS SOLUTION FOR INJECTION, PREFILLED
More informationIn primary biliary cholangitis (PBC), progression
HEPATOLOGY COMMUNICATIONS, VOL. 2, NO. 6, 2018 Clinical Application of the GLOBE and United Kingdom-Primary Biliary Cholangitis Risk Scores in a Trial Cohort of Patients With Primary Biliary Cholangitis
More information2. Liver blood tests and what they mean p2 Acute and chronic liver screen
Hepatology referral pathways for GP 1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for hepatology referral 3. Raised
More informationABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust
ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationAutoimmune and cholestatic liver diseases
Autoimmune and cholestatic liver diseases Prof. Tom Hemming Karlsen Research Institute of Internal Medicine & Department of Transplantation Medicine University of Oslo & Oslo University Hospital, Norway
More informationInterpreting Liver Function Tests
PSH Clinical Guidelines Statement 2017 Interpreting Liver Function Tests Dr. Asad A Chaudhry Consultant Hepatologist, Chaudhry Hospital, Gujranwala, Pakistan. Liver function tests (LFTs) generally refer
More informationPBC features and management in the era of UDCA and Budesonide
PBC features and management in the era of UDCA and Budesonide Raoul Poupon, MD Université P&M Curie, AP-Hôpitaux de Paris, Inserm, Paris, France The changing pattern of PBC Over the last 2 decades: More
More informationPrimary biliary cholangitis (PBC)
The PBC Network Primary biliary cholangitis (PBC) Living with your diagnosis Officially endorsed and reviewed by About this guide The European Association for the Study of the Liver (EASL) is a major European
More informationMrs Janet Catt. Pre-Conference Nurse s Course. Royal Free London NHS Foundation Trust. Janet Catt MSc RN Lead Nurse Specialist Practic 12/12/2014
Pre-Conference Nurse s Course in partnership with Mrs Janet Catt Royal Free London NHS Foundation Trust Janet Catt MSc RN Lead Nurse Specialist Practic 1 Liver blood tests monitoring cirrhosis HIV/HCV
More informationInvestigating and Referring Incidental Findings of Abnormal Liver Tests
Investigating and Referring Incidental Findings of Abnormal Liver Tests Note on Referral Guidelines: these revised guidelines are presented as a tool to aid appropriate referral and management of common
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationIdiopathic adulthood ductopenia manifesting as jaundice in a young male
Idiopathic adulthood ductopenia manifesting as jaundice in a young male Deepak Jain*,1, H. K. Aggarwal 1, Avinash Rao 1, Shaveta Dahiya 1, Promil Jain 2 1 Department of Medicine, Pt. B.D. Sharma University
More informationData Sheet. BICALOX 50 mg is a white to off-white, round, film coated, biconvex tablets, engraved with 'BC 50' on one face and plain on the other.
BICALOX Data Sheet Bicalutamide 50 mg tablets Presentation BICALOX 50 mg is a white to off-white, round, film coated, biconvex tablets, engraved with 'BC 50' on one face and plain on the other. Uses Actions
More informationLIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES
LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions
More informationEfficacy and Safety of Seladelpar in Primary Biliary Cholangitis 52-Week Analysis of a Dose-Ranging Phase 2 Study
Efficacy and Safety of Seladelpar in Primary Biliary Cholangitis 52-Week Analysis of a Dose-Ranging Phase 2 Study Bowlus CL, Neff G, Aspinall R, Galambos M, Goel A, Hirschfield G, Kremer AE, Mayo MJ, Swain
More informationObeticholic Acid for the Treatment of Primary Biliary Cholangitis: Comparative Clinical Effectiveness, Value, and Value-Based Price Benchmarks
Obeticholic Acid for the Treatment of Primary Biliary Cholangitis: Comparative Clinical Effectiveness, Value, and Value-Based Price Benchmarks Evidence Report July 26, 2016 Institute for Clinical and Economic
More informationGEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN CENTRAL GREECE
GEOEPIDEMIOLOGY OF PRIMARY BILIARY CIRRHOSIS IN CENTRAL GREECE Kalliopi Azariadis 1, Nikolaos K. Gatselis 1, Kalliopi Zachou 1, Vasiliki Lygoura 1, Pinelopi Arvaniti 1, Eirini I. Rigopoulou 1, Georgia
More informationNICE QIPP about Lipitor. Robert Trotter. Clinical Effectiveness Consultant
NICE QIPP about Lipitor Robert Trotter Clinical Effectiveness Consultant LIP2894c Date of preparation: April 2009 Prescribing information for atorvastatin is available on the last slide Roadmap Background
More informationFat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy
Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to
More informationTABLE OF CONTENTS SYMPOSIUM AGENDA. Diagnosis, Stratification of Risk, and Initial Treatment in PBC
PBC Novel Pathways for Treatment of Cholestatic Liver Disease TABLE OF CONTENTS Faculty Biographies SYMPOSIUM AGENDA Introduction Kris V. Kowdley, MD Diagnosis, Stratification of Risk, and Initial Treatment
More informationNational Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008
Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationHHS Public Access Author manuscript Hepatology. Author manuscript; available in PMC 2017 March 01.
Febuxostat-Induced Acute Liver Injury Matt Bohm, DO, Raj Vuppalanchi, MD, Naga Chalasani, MD, and Drug Induced Liver Injury Network (DILIN) Department of Medicine, Indiana University School of Medicine,
More informationLiver Disease That Presents with Jaundice (PBC, Alcohol and Drugs): Diagnosis and Patient Management. Emma Pham, PA-C
Liver Disease That Presents with Jaundice (PBC, Alcohol and Drugs): Diagnosis and Patient Management Emma Pham, PA-C Case: JL (jaundiced lady) A 72 year old woman presents to her primary care provider
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Ursodeoxycholic acid 250mg Hard Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each hard gelatin capsule contains Ursodeoxycholic
More informationWEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry
MPharm Programme Liver Biochemistry Slide 1 of 49 MPHM Liver Biochemistry Learning Outcomes Assess and evaluate the signs and symptoms of illness Assess and critically appraise a patients medication regimen,
More informationPrimary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study
LINDOR ET AL. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases Keith D. Lindor 1, Christopher L. Bowlus 2, James Boyer 3, Cynthia Levy 4,
More informationMr Ricky Gellissen Imperial College Healthcare NHS Trust, London, UK
Mr Ricky Gellissen Imperial College Healthcare NHS Trust, London, UK Ms Sally Bufton University Hospital Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham Mrs Janet Catt Royal Free
More informationPrimary biliary cirrhosis (PBC) is an autoimmune
Early Biochemical Response to Ursodeoxycholic Acid and Long-Term Prognosis of Primary Biliary Cirrhosis: Results of a 14-Year Cohort Study Li-Na Zhang, 1,2 * Tian-Yan Shi, 1,2 * Xu-Hua Shi, 1,2 Li Wang,
More informationFIS 2013, Birmingham
Fidaxomicin: CDDFT Case Studies Dr Deepa Nayar County Durham and Darlington Foundation Trust FIS 2013, Birmingham This meeting has been initiated and funded by Astellas Pharma Ltd. County Durham and Darlington
More informationPresentation and mortality of primary biliary cirrhosis in older patients
Age and Ageing 2000; 29: 305 309 Presentation and mortality of primary biliary cirrhosis in older patients JULIA L. NEWTON 1,DAVID E. JONES 2,JANE V. METCALF 2,JAY B. PARK 2,ALISTAIR D. BURT 2, MARGARET
More informationNew Zealand Datasheet. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Bicalutamide 50 mg film coated tablets
New Zealand Datasheet 1 PRODUCT NAME Binarex 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Bicalutamide 50 mg film coated tablets 3 PHARMACEUTICAL FORM Binarex tablets are white to off-white, circular, biconvex,
More informationCASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease
CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease Maria Isabel Fiel, M.D. The Mount Sinai Medical Center New York, New York Case A 57 yo man, 7 months
More informationOverview of PSC Making the Diagnosis
Overview of PSC Making the Diagnosis Tamar Taddei, MD Assistant Professor of Medicine Yale University School of Medicine Overview Definition Epidemiology Diagnosis Modes of presentation Associated diseases
More informationHepatology for the Nonhepatologist
Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning
More information2. Liver blood tests and what they mean p2 Acute and chronic liver screen
1 Scope For use within hepatology Contents 2. Liver blood tests and what they mean p2 Acute and chronic liver screen p2 Common reasons for referral 3. Raised ALT +/- GGT p3 4. Non alcoholic fatty liver
More informationDATA SHEET URSOFALK. Ursodeoxycholic Acid
URSOFALK - New Zealand Page 1 of 7 NAME OF DRUG DATA SHEET URSOFALK Ursodeoxycholic Acid DESCRIPTION Ursodeoxycholic acid (UDCA) is a white or almost white powder. It is practically insoluble in water,
More informationInformation leaflet for primary care: Agomelatine
Information leaflet for primary care: Agomelatine Background information Agomelatine is an antidepressant indicated for the treatment of major depressive episodes in adults. Agomelatine is a melatonin
More informationManagement of cholestatic diseases Today and tomorrow
12th Paris Hepatology Conference Management of cholestatic diseases Today and tomorrow Paris 15 January 2019 U. Beuers Department of Gastroenterology & Hepatology Tytgat Institute for Liver and Intestinal
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Comfora 595 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains: glucosamine sulphate
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze
More informationAutoimmune Liver Disease
Autoimmune Liver Disease A Guide An explanation of what autoimmune liver diseases are including autoimmune hepatitis and autoimmune sclerosis cholangitis What are autoimmune diseases?... 4 What is autoimmune
More informationPrimary Biliary Cirrhosis : NOT ANY MORE!! PRIMARY BILIARY CHOLANGITIS
Primary Biliary Cirrhosis : NOT ANY MORE!! PRIMARY BILIARY CHOLANGITIS Nikolaos T. Pyrsopoulos, MD, PhD, MBA, FACP, AGAF, FAASLD Associate Professor and Chief, Division of Gastroenterology and Hepatology
More informationAESOP Overview and Inclusion/Exclusion Criteria Richard Pencek, PhD
747-207 AESOP Overview and Inclusion/ Criteria Richard Pencek, PhD Sr Director, Clinical Research, Intercept Pharmaceuticals, Inc. 2 PSC Forum 2 AESOP: A Phase 2 Randomized, Placebo-Controlled Trial, Dose-Finding
More informationContinence PGD transdermal oxybutynin Kentera patch 36mg
Continence PGD transdermal oxybutynin Kentera patch 36mg Patient group direction for the supply of transdermal oxybutynin Kentera patch 36mg to patients suffering from urinary frequency, urgency or incontinence
More informationCHOLESTAGEL 625 mg Genzyme
CHOLESTAGEL 625 mg Genzyme 1. NAME OF THE MEDICINAL PRODUCT Cholestagel 625 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 625 mg colesevelam hydrochloride (hereafter
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function / liver function
More information